mifamurtide

(redirected from Mepact)

mifamurtide

A fully synthetic lipophilic derivative of muramyl dipeptide, which is an immune stimulatory component of cell walls from Mycobacterium, used to manage high-grade, non-metastasising, resectable osteosarcoma after surgical excision in children to young adults (age 2 to 30).
 
Adverse effects
Fever (90%), tachycardia (50%), constipation (10%), vomiting, fatigue, infections, anaemia, anorexia, headache, diarrhoea.

Prognosis
Mifamurtide-treated patients have a 30% lower mortality than those treated with chemotherapy.
References in periodicals archive ?
M2 PHARMA-October 26, 2011-Takeda's Mepact secures NICE recommendation for treating bone cancer in children, young people(C)2011 M2 COMMUNICATIONS
Three of the drugs were approved by the EMA but not by the FDA: Ceplene (histamine dihydrochloride), Mepact (mifamurtide), and Yondelis (trabectedin).
The company performed a complete CMC documentation analysis of IDM Pharma's orphan medicinal product, MEPACT.
M2 PHARMA-September 8, 2011-Takeda's bone cancer medicine Mepact gains NICE recommendation(C)2011 M2 COMMUNICATIONS
M2 PHARMA-October 8, 2010-Takeda's osteosarcoma drug Mepact fails to gain NICE recommendation(C)2010 M2 COMMUNICATIONS
8 February 2010 - Japanese Takeda Pharmaceutical Company Limited (TYO: 4502) and its wholly-owned subsidiary, Takeda Pharmaceuticals Europe Limited, said last Monday that Mepact (mifamurtide), a treatment to improve survival in patients with osteosarcoma (malignant bone cancer), is now commercially available in the European Union (EU).